However, Dunleavy and colleagues reported that 70.8% of MYC + DLBCL patients treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) were PET positive after two cycles of treatment [18]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.